Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

  • End date
    Aug 23, 2025
  • participants needed
  • sponsor
    University Hospitals Bristol NHS Foundation Trust
Updated on 23 January 2021


90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to determine the difference in progression free survival between the 2 groups. If results at that stage suggest a potential benefit then the trial will be developed further to accrue 70 more patients.


This is a prospective multicentre, randomised, open label, study comparing the efficacy and the safety of six 3-weekly cycles cabazitaxel versus 18 x weekly paclitaxel given as first line chemotherapy treatment in patients with HER2-normal metastatic breast cancer. Randomisation will be conducted by a 1:1 ratio.

Condition HER2 Negative Metastatic Breast Cancer
Treatment Paclitaxel, Cabazitaxel
Clinical Study IdentifierNCT03048942
SponsorUniversity Hospitals Bristol NHS Foundation Trust
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent
Metastatic breast cancer fit to receive cytotoxic chemotherapy for metastatic disease
Measurable disease as per RECIST 1.1
HER2 negative defined as ICH 0+, 1+ or 2+ and FISH/SISH/CISH(ration<2.0) in the case of IHC 2+
ECOG performance status 0 or 1
ER+ve or ER-ve
Female age 18 years
Anticipated life expectancy > 6 months
Haemoglobin >10.0g/DL
Absolute neutrophil count>1.5 x 10^9/L
Platelet count>100 x 10^9/L
Serum creatinine <1.5 x ULN
Negative pregnancy test for all women of child bearing potential

Exclusion Criteria

Grade 2 oral mucositis or peripheral or sensory neuropathy
History of other malignancy
History of severe hypersensitivity grade 3 to polysorbate 80- containing drugs and taxanes
Clinically significant cardiovascular disease
Any acute or chronic medical condition
Acute infection requiring systemic antibiotics or antifungal medication
Sex hormones
Administration of any live vaccine within 8 weeks
Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5
Participation in another clinical trial with an investigational drug within 30 days of randomisation
Pregnant or breast feeding women
Contraindications to the use of corticosteroid treatment
HER2 Positive breast cancer
Previous Paclitaxel chemotherapy in the adjuvant setting
Previous cytotoxic chemotherapy for metastatic disease
Palliative radiotherapy for metastatic disease within 4 weeks of randomisation
Symptomatic brain metastases confirmed with CT/MRI brain
History of other malignancy
Grade 2
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note